India’s molecular point-of-care testing market is expanding beyond respiratory infections, with growth opportunities emerging across disease areas and healthcare settings.
Molbio Diagnostics’ IPO brings investor attention to a segment of India’s diagnostics ecosystem undergoing a structural transformation: molecular testing is moving closer to the point of care while expanding across a broader range of infectious diseases.
As the industry report partner for Molbio Diagnostics’ IPO, 1Lattice assessed the structural shifts shaping India’s molecular point-of-care testing (POCT) opportunity, from the decentralization of testing to expansion across disease areas and broader adoption of multi-disease platforms.
Industry outlook: An INR 152.1B molecular POCT opportunity by FY31P
India’s molecular POCT market for infectious diseases is projected to grow from INR 61.6B in FY26 to INR 152.1B by FY31P, implying a 19.8% CAGR, accelerating from 13.9% during FY21–26.
Respiratory infections are expected to remain the largest opportunity, but the next phase of growth is becoming increasingly multi-disease.
While respiratory POCT is projected to grow at a 17.5% CAGR during FY26–31P, the underlying chart indicates faster expansion in certain emerging applications, including tropical diseases (55.8%) and hepatitis (20.9%).
The opportunity is therefore not only about increasing molecular test volumes, but also about expanding where, for which diseases, and how extensively molecular POCT platforms can be deployed.
India’s molecular POCT opportunity is evolving from a respiratory-led testing market toward a broader, decentralized, and multi-disease diagnostics ecosystem.
What does this mean for companies participating in molecular diagnostics?
A growing market is only the starting point. Investors increasingly need to understand:
- Addressable disease pool → How broad is the range of diseases that can be addressed through the platform?
- Platform utilization → Can an expanding assay menu drive greater utilization of the installed platform base?
- Decentralization opportunity → How effectively can molecular testing move closer to the patient?
- Adoption pathways → How diversified is adoption across public health programs and broader healthcare settings?
- Company positioning → How is the company positioned within an evolving molecular diagnostics landscape?
From market sizing to investment-grade industry positioning
For Molbio, 1Lattice connected the dots across:
- Market evolution
- Disease-area growth pools
- Platform adoption
- Competitive dynamics
- Company positioning
1Lattice | Industry Reports for Capital Markets
1Lattice helps companies, bankers, and investors move beyond market sizing to build evidence-backed, investor-ready industry narratives around market structure, growth opportunities, and competitive positioning.
Explore the Molbio molecular diagnostics industry report: Molbio Molecular Diagnostics Industry Report
Preparing for an IPO, QIP, or strategic transaction?
A robust industry narrative can strengthen the overall equity story by connecting market opportunity, industry dynamics, and company positioning.
